Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries

Cardiovascular Research

Volumn 64, Issue 1, 2004, Pages 165-171

  Banai, Shmuel ^a   Gertz, S David ^b   Gavish, Lilach ^b   Chorny, Michael ^c   Perez, Louise S ^b   Lazarovichi, Galila ^b   Ianculuvich, Mickey ^b   Hoffmann, Michael ^d   Orlowski, Michael ^d   Golomb, Gershon ^c   Levitzki, Alexander ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d Eurocor GmbH   (Germany)

Author keywords

Angioplasty; Coronary intervention; Restenosis; Stents; Tyrosine protein kinases

Indexed keywords

POLYGLACTIN; POLYMER; TYRPHOSTIN; TYRPHOSTIN AGL 2043; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTIMA; MORPHOMETRICS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; CORONARY DISEASE; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; MODELS, ANIMAL; PROTEIN-TYROSINE KINASES; STENTS; SWINE; SWINE, MINIATURE; TUNICA INTIMA; TYRPHOSTINS;

EID: 4444231182     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.06.013     Document Type: Article

References (31)

1. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation. 96:1997;4083-4094
2. Welt F., Edelman E. Cell cycle regulation and control of angioplasty restenosis. Adv. Drug Deliv. Rev. 24:1997;45-51
3. Blank R.S., Owens G.K. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J. Cell. Physiol. 142:1990;635-642
4. Grotendorst G.R., Chang T., Seppa H.E., et al. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J. Cell. Physiol. 113:1982;261-266
5. Buetow B.S., Tappan K.A., Crosby J.R., et al. Chimera analysis supports a predominant role of PDGFRbeta in promoting smooth-muscle cell chemotaxis after arterial injury. Am. J. Pathol. 163:2003;979-984
6. Desfaits A.C., Raymond J., Muizelaar J.P. Growth factors stimulate neointimal cells in vitro and increase the thickness of the neointima formed at the neck of porcine aneurysms treated by embolization. Stroke. 31:2000;498-507
7. Ding H., Wang R., Marcel R., Fisher D.Z. Adenovirus-mediated expression of a truncated PDGFbeta receptor inhibits thrombosis and neointima formation in an avian arterial injury model. Thromb. Haemost. 86:2001;914-922
8. Sirois M.G., Simons M., Edelman E.R. Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation. 95:1997;669-676
9. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1788
10. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc. Chem. Res. 36:2003;462-469
11. Levitzki A. Targeting signal transduction for disease therapy. Curr. Opin. Cell Biol. 8:1996;239-244
12. Mohammadi M., McMahon G., Lun L., et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960
13. Kovalenko M., Ronnstrand L., Heldin C.-H., et al. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 36:1997;6260-6269
14. Gazit A., Yee K., Uecker A., et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg. Med. Chem. 11:2003;2007-2018
15. Banai S., Wolf Y., Golomb G., et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 97:1998;1960-1969
16. Fishbein I., Waltenberger J., Banai S., et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler. Thromb. Vasc. Biol. 20:2000;667-676
17. Fishbein I., Chorny M., Banai S., et al. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler. Thromb. Vasc. Biol. 21:2001;1434-1439
18. Banai S., Chorny M., Gertz S.D., et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials. 2004;. [in press]
19. Movat H.Z. Demonstration of all connective tissue elements in a single section; pentachrome stains. AMA Arch. Pathol. 60:1955;289-295
20. Schwartz R.S., Edelman E.R., Carter A.J., et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 106:2002;1867-1873
21. Lemos P.A., Serruys P.W., Sousa J.E. Drug-eluting stents: cost versus clinical benefit. Circulation. 107:2003;3003-3007
22. O'Neill W.W., Leon M.B. Drug-eluting stents: costs versus clinical benefit. Circulation. 107:2003;3008-3011
23. Kereiakes D.J. Hippocrates revisited: the evidence for drug-eluting stents. Circulation. 107:2003;3012-3014
24. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 104:2001;852-855
25. Kahan B.D. Sirolimus: a comprehensive review. Expert Opin. Pharmacother. 2:2001;1903-1917
26. Edelman E.R., Danenberg H.D. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds? Circulation. 108:2003;6-8
27. Huang S., Houghton P.J. Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4:2001;378-391
28. US Food and Drug Administration, FDA Talk Paper, 2003; T03-71.
29. Yusuf R.Z., Duan Z., Lamendola D.E., et al. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets. 3:2003;1-19
30. Ferlini C., Ojima I., Distefano M., et al. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr. Med. Chem. Anti-Cancer Agents. 3:2003;133-138
31. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89